News - Millennium Pharmaceuticals, Biotechnology

Filter

Popular Filters

Infinity amends PI3K-delta, gamma accord with Millennium

28-12-2012

US drug discovery firm Infinity Pharmaceuticals (Nasdaq: INFI) says it has amended its development and…

BiotechnologyFinancialInfinity PharmaceuticalsIPI-145LicensingMillennium PharmaceuticalsPharmaceuticalRespiratory and PulmonaryTakeda Pharmaceuticals

Novel therapeutic agents presented at ASH provide hope for patients with hard-to-treat blood disorders

11-12-2012

Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting…

Ambit BiosciencesBiotechnologyIncyteMillennium PharmaceuticalsMLN9708NovartisOncologyPharmaceuticalquizartinibResearchruxolitinibTakeda Pharmaceuticals

European Commission grants conditional approval for Adcetris

01-11-2012

Millennium, a wholly owned subsidiary of Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502)…

AdcetrisBiotechnologyEuropeMillennium PharmaceuticalsOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

More highlights from ESMO Congress

02-10-2012

In further news coming out at the European Society of Medical Oncology (ESMO) Congress taking place in…

AdcetrisAstellas PharmaBiotechnologydabrafenibGlaxoSmithKlineImmunoGenMedivationMillennium PharmaceuticalsOncologyPharmaceuticalResearchRocheSeattle GeneticsT-DM1Takeda Pharmaceuticalstrastuzumab emtansineXtandi

US FDA approves Seattle Genetics’ Adcetris to treat two types of lymphoma

22-08-2011

Shares of US biotech firm Seattle Genetics Nasdaq: SGEN) gained 8% to $15.09 late Friday, after the US…

AdcetrisBiotechnologybrentuximabMillennium PharmaceuticalsNorth AmericaOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

Back to top